Cell death-based treatment of lung adenocarcinoma | Cell Death & Disease
Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer | American Journal of Physiology-Gastrointestinal and Liver Physiology
Frontiers | Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer | Medicine
Alectinib for treatment of ALK-positive non-small-cell lung cancer | Future Oncology
The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain - Chen - 2020 - Cancer Medicine - Wiley Online Library
Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras - Song - 2021 - MedComm - Wiley Online Library
Ceritinib (LDK378) | ≥99%(HPLC) | Selleck | ALK inhibitor
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy - ScienceDirect
Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer - Katayama - 2018 - Cancer Science - Wiley Online Library
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. - ppt download
Ceritinib | C28H36ClN5O3S - PubChem
Zykadia (Ceritinib) for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) - Clinical Trials Arena
Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer - Oncology Nurse Advisor
Frontiers | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC | Oncology
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies - European Journal of Cancer
Pharmaceuticals | Free Full-Text | The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer | HTML
Mechanisms of resistance to crizotinib. | Download Scientific Diagram
Frontiers | The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer | Oncology
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer - ScienceDirect
Ceritinib - Wikipedia
OncoPrescribe - Write The Perfect Prescription
ZYKADIA™ (ceritinib) - Cancer Therapy Advisor
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective - ScienceDirect
Targeting MYCN and ALK in resistant and relapsing neuroblastoma
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry
Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET - ScienceDirect
Ceritinib
Mechanisms of resistance to crizotinib. | Download Scientific Diagram
